Skip main menu Accessibility Free guides | Investor relations | Careers | About us | Contact us | Press
My accounts Log in/out

Hargreaves Lansdown
 
Richard Troue

Schroder Income Fund – Research Update

By Richard Troue | Thu 29 July 2010

Kevin Murphy and Nick Kirrage took over management of the Schroder Income Fund on 18 May 2010; we recently met up with them to see how they were getting on.

Prior to taking on full responsibility for the fund they had worked with the previous managers very closely as part of the Schroder Specialist Value UK Equity Team. They’ve also built a strong track record managing the Schroder Recovery Fund since 01 July 2006. They’ll continue to manage the Recovery Fund alongside the Income Fund.

When the announcement was made we didn’t feel existing investors should have cause for concern. We see no reason to alter our stance following the recent meeting. The two funds have a great deal in common and are managed using a similar approach which has proved successful in the past. Approximately 80% of the shares held in the Income Fund are also held in the Recovery Fund.

Given the overlap no significant changes are expected to either the objective or style of the Income Fund. The managers will continue to focus on achieving a rising income with the potential for capital growth over the long term. However, this is not guaranteed and the value of any investment will fall in value as well as rise.

Kevin Murphy and Nick Kirrage will concentrate on companies with lower levels of debt and which are able to generate large amounts of cash. They believe companies exhibiting these characteristics will be better placed to grow their dividend over the long term.

They currently have over 30% of the fund invested in the financial sector believing many banks to have stable and profitable core businesses. They also believe the Financial Services Authority (FSA), the regulator, has conducted adequate tests to ensure banks are better prepared to cope with further weakness in the economy.

They are also positive on healthcare companies, including pharmaceutical giant AstraZeneca which currently yields approximately 4.4% and is the fund’s largest holding at around 5.2% of the portfolio. The fund also retains the maximum 20% exposure to non-UK holdings, which include cash, bonds and overseas stocks. This diversifies the fund but adds additional risks.

One significant change they have made since taking over is increasing the fund’s weighting in BP from around 2% to just under 4% of the portfolio. They considered the large falls in the share price to represent a good buying opportunity despite the company’s announcement it was to suspend its dividend payment. They retain the belief that despite the scale of the disaster BP remains highly cash generative and is strong enough to thrive once again.

Given the experience of Kevin Murphy and Nick Kirrage and their familiarity with the process used on the Income Fund we have confidence in their ability to achieve good returns over the long term. We therefore believe existing investors should generally continue to hold. Although not currently, please note the fund can be concentrated which increases risk. This fund is not currently on the Wealth 150 list of our favourite funds in each sector.


% Growth 01/07/2005 to 03/07/2006% Growth 03/07/2006 to 02/07/2007% Growth 02/07/2007 to 01/07/2008% Growth 01/07/2008 to 01/07/2009% Growth 01/07/2009 to 01/07/2010
Schroder Income Acc14.3218.34-21.760.5219.82
Schroder Recovery Acc19.1517.02-23.584.3119.69
IMA UK Equity Income17.216.19-20.52-16.0217.51

Past performance is not a guide to the future. Source: Lipper Hindsight

Schroder Income Fund

Initial charge 5.25%
Initial saving 5.25%
Annual charge 1.50%
Annual saving 0.25%*

*Annual saving is not available in the SIPP

Find out more about this fund including how to invest

Please read the key features of the Schroder Income Fund in addition to the information above

Key features of the Schroder Income Fund

Schroder Recovery Fund

Initial charge 5.25%
Initial saving 5.00%
Annual charge 1.25%
Annual saving 0.25%*

*Annual saving is not available in the SIPP

Find out more about this fund including how to invest

Please read the key features of the Schroder Recovery Fund in addition to the information above

Key features of the Schroder Recovery Fund
The value of investments can go down as well as up, this means you could get back less than you invested. Therefore all investments should be regarded with a long term view. No news or research item is a personal recommendation to deal. If you are unsure about the suitability of an investment please contact us for advice.

Recent funds news

Rob Morgan

Liontrust Special Situations - fund update

By Rob Morgan | Thu 09 February 2012
Globalisation has transformed many firms’ growth potential. Previously UK-centric industries, such as engineering, are now transacting more business overseas.

Rob Morgan

AXA Framlington Managed Balanced Fund - research update

By Rob Morgan | Wed 08 February 2012
Richard Peirson has seen his fair share of market ups and downs during his 18 years at the helm of the AXA Framlington Managed Balanced Fund. He has one of the longest track records in the sector, and indeed the industry.

Richard Troue

Courage of conviction - GLG Japan CoreAlpha Fund

By Richard Troue | Tue 07 February 2012
An important aspect of our research is to regularly interview fund managers. We quiz them on all aspects of their fund. We are looking for a robust analytical process, clear and concise views, and the willingness to support these views with a high level of conviction.

Meera Patel

Newton Continental European Fund - research alert

By Meera Patel | Mon 06 February 2012
Following a recent review of the European sector, the Newton Continental European Fund came under the spotlight for its below average performance.

Meera Patel

Aberdeen Emerging Markets Fund - removal from Wealth 150

By Meera Patel | Fri 03 February 2012
The Aberdeen Emerging Market Fund has been removed from the Wealth 150 list of our favourite funds for new investment.



Hargreaves Lansdown is authorised and regulated by the Financial Services Authority.

Disclaimer | Important Investment Notes | Terms & Conditions | Privacy Policy | Site map | Email this to a friend | Accessibility